Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 12Carcinoma, Non-Small-Cell Lung 6Lung Neoplasms 5Breast Diseases 4Thoracic Neoplasms 3Respiratory Tract Neoplasms 3Neoplasms 3Lung Diseases 3Bronchial Neoplasms 3Neoplasms, Glandular and Epithelial 2Neoplasms by Histologic Type 2Melanoma 2Kidney Neoplasms 2Endocrine Gland Neoplasms 2Digestive System Neoplasms 2Respiratory Tract Diseases 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Mammary Neoplasms, Animal 1Hodgkin Disease 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Bronchogenic 1Advanced Breast Cancer 1

Interventions

relacorilant 1olaparib 1niraparib 1liposomal doxorubicin 1entinostat 1avelumab 1Trabectedin 1Ocoxin 1Gemcitabine 1Dexamethasone 1Cell Count 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Ovarian Diseases × entinostat × Clear all
NCT02915523 2024-01-10

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

Syndax Pharmaceuticals

Phase 1/2 Completed
140 enrolled 25 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡